Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer

NCT04024800 is registered in ClinicalTrials.gov with NuGenerex Immuno-Oncology as lead sponsor.

NCT NCT04024800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04024800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer
Lead sponsor
NuGenerex Immuno-Oncology
Phase
Phase 2
Overall status
Unknown status
Start date
May 3, 2019
Completion date
June 30, 2024
Enrollment
29 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer